Encelto (Revakinagene Taroretcel-Lwey) for Ohio Only
Customize your policy alerts
Sign up for UnitedHealthcare Policy CSOH2026D0137.B alerts
Get alerted when Policy CSOH2026D0137.B changes without checking for updates manually.
Monitor payer policy activity
UnitedHealthcare Community Plan medical benefit drug policy governing coverage of Encelto for adults with idiopathic macular telangiectasia type 2 in Ohio, subject to medical-necessity criteria, prior authorization, dosing limits, and applicable Ohio requirements.
The References section was updated to reflect the most current information, and the prior policy version was archived.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.